Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

DBV Technologies S.A. DBVT NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • FR • USD

SharesGrow Score
57/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$46.33
+118%

DBV Technologies S.A. (DBVT) is a Biotechnology company in the Healthcare sector, currently trading at $21.25. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is DBVT = $46 (+118% upside).

Valuation: DBVT trades at a trailing Price-to-Earnings (P/E) of -5.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.08.

Net income is $147M (loss), growing at -20.5%/yr. Net profit margin is 0% (thin). Gross margin is -165.8% (+157.1 pp trend).

Balance sheet: total debt is $22M against $169M equity (Debt-to-Equity (D/E) ratio 0.13, conservative). Current ratio is 3.67 (strong liquidity). Debt-to-assets is 9.3%. Total assets: $234M.

Analyst outlook: 10 / 15 analysts rate DBVT as buy (67%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 48/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 21/100 (Fail), Future 73/100 (Pass), Income ?/100 (Fail).

$46.33
▲ 118.02% Upside
Average Price Target
Based on 15 Wall Street analysts offering 12-month price targets for DBV Technologies S.A., the average price target is $46.33, with a high forecast of $51.00, and a low forecast of $40.00.
Highest Price Target
$51.00
Average Price Target
$46.33
Lowest Price Target
$40.00

DBVT SharesGrow Score Overview

68/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 48/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 21/100
Gross margin is + market cap
FUTURE 73/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — DBVT

✓
VALUE Pass
100/100
DBVT trades at a trailing Price-to-Earnings (P/E) of -5.5 (S&P 500 average ~25). Forward PEG 0.08 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $46, implying +116.5% from the current price $21. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
48/100
DBVT: +14.7%/yr revenue is, -20.5%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet DBVT: Debt-to-Equity (D/E) ratio 0.13 (conservative), Current ratio is 3.67 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
21/100
DBVT: Gross margin is -165.8% (+157.1 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 21/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
73/100
Analyst outlook: 10 / 15 analysts rate DBVT as buy (67%). Analyst consensus target is $46 (+116.5% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range6.46-26.185
Volume193.1K
Avg Volume (30D)325.22K
Market Cap$508.34M
Beta (1Y)-0.20
Share Statistics
EPS (TTM)-5.30
Shares Outstanding$27.91M
IPO Date2014-10-22
Employees106
CEODaniel Tassé
Financial Highlights & Ratios
Gross Profit$-17.67M
EBITDA$-135.49M
Net Income$-147.4M
Operating Income$-153.16M
Total Cash$194.17M
Total Debt$21.68M
Net Debt$-172.48M
Total Assets$233.72M
Price / Earnings (P/E)-4
Analyst Forecast
1Y Price Target$48.00
Target High$51.00
Target Low$40.00
Upside+125.9%
Rating ConsensusBuy
Analysts Covering15
Buy 67% Hold 27% Sell 7%
Price Target Summary
Company Info
CountryFR
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS23306J3095

Price Chart

Track all markets on TradingView
DBVT
DBV Technologies S.A. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
6.46 52WK RANGE 26.19

People Also View

NUVL
NUVL
Nuvalent, Inc.
$104.75
-0.26%
 CELC
CELC
Celcuity Inc.
$123.47
+2.17%
 CNTA
CNTA
Centessa Pharmaceuticals plc
$39.61
+0.05%
 OPT
OPT
Opthea Limited
$3.41
+1.49%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.70
+1.63%
 TARS
TARS
Tarsus Pharmaceuticals, Inc.
$71.80
-2.72%
 PNT
PNT
POINT Biopharma Global Inc.
$12.50
+0.16%
 INBX
INBX
Inhibrx Biosciences, Inc.
$83.60
+0.49%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message